Literature DB >> 28768163

A protocol for quantitative analysis of murine and human amyloid-β1-40 and 1-42.

Tomer Illouz1, Ravit Madar2, Kathleen Griffioen3, Eitan Okun4.   

Abstract

BACKGROUND: Amyloid-β (Aβ), a hallmark of Alzheimer's disease (AD), has long been a focus of basic and translation research in AD. Quantification and dissociation of the Aβ fractions in their soluble and insoluble forms, is a key factor in numerous AD studies. NEW
METHOD: Here we provide a generalized sandwich-enzyme-linked-immuno-sorbent-assay (sELISA) protocol for quantification of human and murine Aβ1-40 and Aβ1-42 and dissociation of these peptides to their soluble-oligomeric and insoluble-fibrillar forms.
RESULTS: We have validated the levels of soluble and insoluble Aβ1-40 and Aβ1-42 in the 5XFAD AD and the Ts65Dn Down-Syndrome (DS) mouse models in both the cortex, hippocampus and blood as follows: (1) blood levels of Aβ1-40 and Aβ1-42 are elevated in both mouse strains. (2) 5XFAD mice exhibit elevated soluble and insoluble Aβ1-40 in cortical and hippocampal tissues, soluble Aβ1-42 in the hippocampus, and insoluble Aβ1-42in both cortical and hippocampal tissues (3) Ts65Dn mice exhibit elevated levels of Aβ1-40 in the cortex. COMPARISON WITH EXISTING
METHODS: Several methodologies have been proposed for the high throughput measure of Aβ, including HPLC-mass-spectrometry, micro-immunoelectrodes, immunoprecipitation and ELISA. Although commercial sELISA kits are widely used, herein, we describe a more accessible and cost-effective in-house protocol enabling to measure either human or murine, soluble and insoluble Aβ1-40 and Aβ1-42 levels.
CONCLUSIONS: We provide a streamlined and accessible protocol for the assessment of soluble and insoluble Aβ1-40 and Aβ1-42 levels from mouse or human origins, enabling a higher accessibility for researchers in the field to generate reliable Aβ-related measurements.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5XFAD; Alzheimer’s disease; Amyloid-beta; Aβ; ELISA; Ts65Dn

Mesh:

Substances:

Year:  2017        PMID: 28768163     DOI: 10.1016/j.jneumeth.2017.07.022

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  5 in total

1.  Maternal antibodies facilitate Amyloid-β clearance by activating Fc-receptor-Syk-mediated phagocytosis.

Authors:  Tomer Illouz; Raneen Nicola; Linoy Ben-Shushan; Ravit Madar; Arya Biragyn; Eitan Okun
Journal:  Commun Biol       Date:  2021-03-12

2.  Therapeutic B-cell depletion reverses progression of Alzheimer's disease.

Authors:  Ki Kim; Xin Wang; Emeline Ragonnaud; Monica Bodogai; Tomer Illouz; Marisa DeLuca; Ross A McDevitt; Fedor Gusev; Eitan Okun; Evgeny Rogaev; Arya Biragyn
Journal:  Nat Commun       Date:  2021-04-12       Impact factor: 14.919

3.  Sleeve Gastrectomy Reduces Glycemia but Does Not Affect Cognitive Impairment in Lean 5xFAD Mice.

Authors:  Itia Samuel; Rachel Ben-Haroush Schyr; Yhara Arad; Tamar Attali; Shira Azulai; Michael Bergel; Aviv Halfon; Liron Hefetz; Tamir Hirsch; Hadar Israeli; Neta Lax; Keren Nitzan; Dana Sender; Sahar Sweetat; Eitan Okun; Hanna Rosenmann; Danny Ben-Zvi
Journal:  Front Neurosci       Date:  2022-08-11       Impact factor: 5.152

4.  Induction of an effective anti-Amyloid-β humoral response in aged mice.

Authors:  Tomer Illouz; Ravit Madar; Tamir Hirsh; Arya Biragyn; Eitan Okun
Journal:  Vaccine       Date:  2021-07-20       Impact factor: 4.169

5.  Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model.

Authors:  Tomer Illouz; Ravit Madar; Arya Biragyn; Eitan Okun
Journal:  Brain Behav Immun       Date:  2018-10-25       Impact factor: 7.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.